Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)

Market Cap	3.55B -2.7%
Revenue (ttm)	378.34M -10.3%
Net Income	-69.66M
EPS	-0.55
Shares Out	126.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,981,500
Average Volume	2,287,208
Open	28.68
Previous Close	28.83
Day's Range	28.00 - 29.36
52-Week Range	23.20 - 41.50
Beta	-0.59
RSI	48.10
Earnings Date	Mar 28, 2026

About SHE:301089

Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, azithromycin, cytosine, 5-fluorocytosine, cytidine, uridine; and other APIs and pharmaceutical intermediates covering antiviral, anti-tumor, and nervous system. The company was founded in 2001 and is ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,551
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301089

Financial Performance

In 2025, SHE:301089's revenue was 378.34 million, a decrease of -10.28% compared to the previous year's 421.69 million. Losses were -69.66 million, 250.3% more than in 2024.